Who Generates More Revenue? Alnylam Pharmaceuticals, Inc. or Evotec SE

Biotech Revenue Battle: Alnylam vs. Evotec

__timestamp	Alnylam Pharmaceuticals, Inc.	Evotec SE
Wednesday, January 1, 2014	50561000	89496000
Thursday, January 1, 2015	41097000	127677000
Friday, January 1, 2016	47159000	164507000
Sunday, January 1, 2017	89912000	257630000
Monday, January 1, 2018	74908000	375405000
Tuesday, January 1, 2019	219750000	446437000
Wednesday, January 1, 2020	492853000	500924000
Friday, January 1, 2021	844287000	618034000
Saturday, January 1, 2022	1037418000	751448000
Sunday, January 1, 2023	1828292000	781426000
Monday, January 1, 2024	2248243000

Unleashing insights

Revenue Race: Alnylam Pharmaceuticals vs. Evotec SE

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and market influence. Over the past decade, Alnylam Pharmaceuticals, Inc. and Evotec SE have been at the forefront of innovation, each striving to outpace the other in revenue generation. From 2014 to 2023, Alnylam Pharmaceuticals has shown a remarkable growth trajectory, with its revenue surging by over 3,500%, reaching a peak in 2023. In contrast, Evotec SE has maintained a steady growth, with its revenue increasing by approximately 770% over the same period. This comparison highlights Alnylam's aggressive expansion strategy, which has allowed it to surpass Evotec SE in recent years. As the biotech industry continues to evolve, these companies' financial performances will be crucial in determining their future market positions.

Published by

U.S. Securities and Exchange Commission

Source link

sec.gov

Date published

17 Jan 2025